A

New medicine

Indication

DTC
Supplement

Date

Abacavir (Ziagen^®)

HIV

50

2005

Abacavir/lamivudine (Kivexa^®)

HIV

50

2005

In combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a TNF-alpha inhibitor.

HOSPITAL ONLY
(4th line agent )

129

112

96

127
110
72

Abiraterone acetate (Zytiga^®) (764/12)

With prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemo-
therapy regimen.

119
116

123
122

129

129

122

119

112

86

122
74

Adalimumab (Humira^®)

Rheumatoid arthritis

34

2003

Adalimumab (Humira^®)

Psoriatic arthritis

55

2006

137
104

Adefovir (Hepsera^®)

Chronic Hepatitis B

50
29

2005
2003

111

Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)

136

Formulary
2nd line choice for DMO in patients unresponsive to ranibizumab treatment
HOSPITAL ONLY

143

136
129

99 
93

Alendronate/colecalciferol (Fosavance^®)

Postmenopausal osteoporosis

54

2005

114
95
86
79

87

Alogliptin (Vipidia^®) (937/14)   

Type 2 diabetes mellitus in adults

141

118

Alteplase (Actilyse Cathflo^®)
(717/11)

Thrombolytic treatment of occluded central venous access devices

113
109

Alteplase (Actilyse^®) (87/04)

Acute ischaemic stroke

37

2004

119
100

Anagrelide (Xagrid^®)

Thrombocythaemia

54
50

2005

Anakinra (Kineret^®)

Rheumatoid arthritis

2002

Anastrozole (Arimidex^®)

ER positive early breast cancer

63
53
37

2006
2005
2004  

Apixaban 2.5mg and 5mg film-coated tablets (Eliquis^®) (836/13)
 

prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF),

Formulary
(Restricted to patients who have poor INR control on warfarin or with allergy to, or incontrollable side effects from coumarin aticoagulants)

125

113

Aprepitant (Emend^®)

Prevention of cisplatin-induced nausea and vomiting

46

2004

Aprepitant (Emend^®) (242/06)

Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy

112
56

Dec 2011
2006

Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy

HOSPITAL ONLY
(2nd line)

129
122

130

Aripiprazole (Abilify^®) (630/10)

Schizophrenia in adolescents 15 years and older

99 
85
52
43

Aug/Sept 2010
Dec 2008
2005
2004

90
82

Asenapine (Sycrest^®) (762/12)

Treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.

116

Atazanavir (Reeyataz^®) (656/10)

HIV

101
86
85
45
44

Dec 10/Jan 2011
Jan/Feb 2009
Dec 2008
2004

Atomoxetine (Strattera^®) (909/13)

ADHD - adults

Formulary
(GP under direction of Mental Health Specialist)

143
132
 

Nov/Dec 2014
Nov/Dec 2013
 

Atomoxetine (Strattera^®)

ADHD - children of 6 years and older or in adolescents

Adjunct to diet for reduction of
elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia or combined  hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate;
Reduction of  total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments or if such treatments are unavailable;
Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

GPs may prescribe under the direction of a paediatric tertiary centre

116

Atorvastatin (Lipitor^®)

Hypercholesterolaemia in children

54

2005

139

Non-formulary - pending
protocol

116
110
96

For the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

144
142
133

119

119

115